{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:06:41Z","timestamp":1764331601652},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s10557-005-2160-x","type":"journal-article","created":{"date-parts":[[2005,9,4]],"date-time":"2005-09-04T12:55:21Z","timestamp":1125838521000},"page":"177-181","source":"Crossref","is-referenced-by-count":9,"title":["Immediate Effects of Fluvastain on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes"],"prefix":"10.1007","volume":"19","author":[{"given":"Enver","family":"Atalar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Secuk","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim C.","family":"Haznedaroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Necla","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Sivri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Aksoyek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenan","family":"Ovunc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferhan","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2160_CR1","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Survival Study (4S). Lancet 1994;344:1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"2160_CR2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001\u20131009.","journal-title":"N Engl J Med"},{"key":"2160_CR3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349\u20131357.","journal-title":"N Engl J Med"},{"key":"2160_CR4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301\u20131307.","journal-title":"N Engl J Med"},{"key":"2160_CR5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615\u20131612.","journal-title":"JAMA"},{"key":"2160_CR6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9149(00)01230-3","volume":"86","author":"HR Arntz","year":"2000","unstructured":"Arntz HR, Agrawal R, Wunderlich W, et al. Benefical effects of pravastatin (\u00b1 colestyramin\/niacin) initiated immediately after a coronary event. (the Randomized Lipid-Coronary Artery Disease [L-CAD] study). Am J Cardiol 2000;86:1293\u20131298.","journal-title":"Am J Cardiol"},{"key":"2160_CR7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711\u20131718.","journal-title":"JAMA"},{"key":"2160_CR8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1053\/euhj.2002.3291","volume":"23","author":"AH Liem","year":"2002","unstructured":"Liem AH, van Boven AJ, Veeger NJ, et al. FLuvastatin On Risk Diminishment after Acute myocardial infarction study group. Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial. Eur Heart J 2002;23:1931\u20131937.","journal-title":"Eur Heart J"},{"key":"2160_CR9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1161\/01.CIR.0000012530.68333.C8","volume":"105","author":"C Heeschen","year":"2002","unstructured":"Heeschen C, Hamm CW, Laufs U, et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins, increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1146\u20131452.","journal-title":"Circulation"},{"key":"2160_CR10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(05)79893-7","volume":"352","author":"M Thomas","year":"1998","unstructured":"Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998;352:1830\u20131831.","journal-title":"Lancet"},{"key":"2160_CR11","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","volume":"21","author":"M Takemoto","year":"2001","unstructured":"Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712\u20131719.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2160_CR12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0163-7258(03)00055-X","volume":"99","author":"AS Wierzbicki","year":"2003","unstructured":"Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95\u2013112.","journal-title":"Pharmacol Ther"},{"key":"2160_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","volume":"86","author":"JK Liao","year":"2002","unstructured":"Liao JK. Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol 2002;86:5\u201318.","journal-title":"Int J Cardiol"},{"issue":"Suppl S","key":"2160_CR14","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0735-1097(02)02833-4","volume":"41","author":"R Corti","year":"2003","unstructured":"Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003;41(Suppl S):7S\u201314S.","journal-title":"J Am Coll Cardiol"},{"key":"2160_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-5273(00)00325-9","volume":"76","author":"KK Koh","year":"2000","unstructured":"Koh KK. Effects of HMG-CoA reductase inhibitors on hemostasis. Int J Cardiol 2000;76:23\u201332.","journal-title":"Int J Cardiol"},{"issue":"suppl","key":"2160_CR16","doi-asserted-by":"crossref","first-page":"3H","DOI":"10.1016\/S0002-9149(03)00428-4","volume":"91","author":"AP Selwyn","year":"2003","unstructured":"Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 2003;91(suppl)3H\u201311H.","journal-title":"Am J Cardiol"},{"key":"2160_CR17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V69.2.645.645","volume":"69","author":"LV Rao","year":"1987","unstructured":"Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69:645\u2013651.","journal-title":"Blood"},{"key":"2160_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V71.2.335.335","volume":"71","author":"GJ Broze Jr","year":"1988","unstructured":"Broze GJ Jr, Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988;71:335\u2013343.","journal-title":"Blood"},{"key":"2160_CR19","doi-asserted-by":"crossref","first-page":"26486","DOI":"10.1016\/S0021-9258(18)47220-1","volume":"269","author":"K Fukudome","year":"1994","unstructured":"Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C\/activated protein C receptor. J Biol Chem 1994;269:26486\u201326491.","journal-title":"J Biol Chem"},{"key":"2160_CR20","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1073\/pnas.93.19.10212","volume":"93","author":"DJ Stearns-Kurosawa","year":"1996","unstructured":"Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996;93:10212\u201310216.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2160_CR21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0038-1657503","volume":"78","author":"CT Esmon","year":"1997","unstructured":"Esmon CT, Ding W, Yasuhiro K et al. The protein C pathway: New insights. Thromb Haemost 1997;78:70\u201374.","journal-title":"Thromb Haemost"},{"key":"2160_CR22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1172\/JCI119548","volume":"100","author":"S Kurosawa","year":"1997","unstructured":"Kurosawa S, Stearns-Kurosawa DJ, Hidari N, et al. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997;100:411\u2013418.","journal-title":"J Clin Invest"},{"key":"2160_CR23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0002-9149(02)02711-X","volume":"90","author":"F Colivicchi","year":"2002","unstructured":"Colivicchi F, Guido V, Tubaro M, et al. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. Am J Cardiol 2002;90:872\u2013874.","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"2160_CR24","doi-asserted-by":"crossref","first-page":"9B","DOI":"10.1016\/S0002-9149(02)03268-X","volume":"91","author":"S Kinlay","year":"2003","unstructured":"Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003;91(suppl)9B\u201313B.","journal-title":"Am J Cardiol"},{"key":"2160_CR25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.7326\/0003-4819-129-12-199812150-00010","volume":"129","author":"IJ Kullo","year":"1998","unstructured":"Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: Pathobiology and clinical implications. Ann Intern Med 1998;129:1050\u20131060.","journal-title":"Ann Intern Med"},{"key":"2160_CR26","first-page":"2099","volume-title":"Heart Disease: A Textbook of Cardiovascular Medicine","author":"AI Schafer","year":"2001","unstructured":"Schafer AI, Ali NM, Levine GN. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Braunwald ed. Heart Disease: A Textbook of Cardiovascular Medicine, 6th edition. Philadelphia: W.B. Saunders {Company} 2001:2099\u20132132.","edition":"6"},{"key":"2160_CR27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.95.3.594","volume":"95","author":"V Toschi","year":"1997","unstructured":"Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594\u201399.","journal-title":"Circulation"},{"key":"2160_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V71.1.1.1","volume":"71","author":"Y Nemerson","year":"1988","unstructured":"Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1\u20138.","journal-title":"Blood"},{"key":"2160_CR29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V69.2.645.645","volume":"69","author":"LV Rao","year":"1987","unstructured":"Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69:645\u2013651.","journal-title":"Blood"},{"key":"2160_CR30","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1016\/S0021-9258(18)68737-X","volume":"263","author":"TC Wun","year":"1998","unstructured":"Wun TC, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1998;263:6001\u20136004.","journal-title":"J Biol Chem"},{"key":"2160_CR31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V71.2.335.335","volume":"71","author":"GL Broze Jr","year":"1988","unstructured":"Broze GL Jr, Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988;71:335\u2013343.","journal-title":"Blood"},{"key":"2160_CR32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/338518a0","volume":"338","author":"JJ Girard","year":"1989","unstructured":"Girard JJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518\u2013520.","journal-title":"Nature"},{"key":"2160_CR33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/oxfordjournals.jbchem.a123818","volume":"111","author":"K Enjyoji","year":"1992","unstructured":"Enjyoji K, Emi M, Mukai T, et al. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem 1992;111:681\u2013687.","journal-title":"J Biochem"},{"key":"2160_CR34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","volume":"336","author":"The RISC Group","year":"1990","unstructured":"The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827\u2013830.","journal-title":"Lancet"},{"issue":"8656","key":"2160_CR35","first-page":"182","volume":"2","author":"The SCATI (Studio sulla Calciparina nell\u2019Angina e nella Trombosi Ventricolare nell\u2019Infarto) Group","year":"1989","unstructured":"The SCATI (Studio sulla Calciparina nell\u2019Angina e nella Trombosi Ventricolare nell\u2019Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;2(8656):182\u2013186.","journal-title":"Lancet"},{"key":"2160_CR36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/ard.60.12.1149","volume":"60","author":"I Ertenli","year":"2001","unstructured":"Ertenli I, Kiraz S, Celik I, et al. Changes in the concentration and distribution of tissue factor pathway inhibitor in Beh\u00e7et\u2019s disease and systemic lupus erythematosus: Effect on the prethrombotic state. Ann Rheum Dis 2001;60:1149\u20131151.","journal-title":"Ann Rheum Dis"},{"key":"2160_CR37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-5273(00)00345-4","volume":"75","author":"N Yamamoto","year":"2000","unstructured":"Yamamoto N, Ogawa H, Oshima S, et al. The effect of heparin on tissue factor pathway inhibitor in patients with acute myocardial infarction. Int J Cardiol 2000;75:267\u2013274.","journal-title":"Int J Cardiol"},{"key":"2160_CR38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0049-3848(98)00147-9","volume":"93","author":"H Soejima","year":"1999","unstructured":"Soejima H, Ogawa H, Yasue H, et al. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb Res 1999;93:17\u201325.","journal-title":"Thromb Res"},{"key":"2160_CR39","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.V95.5.1687.005k08_1687_1693","volume":"95","author":"JM Gu","year":"2000","unstructured":"Gu JM, Katsuura Y, Ferrell GL, et al. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood 2000;95:1687\u20131693.","journal-title":"Blood"},{"key":"2160_CR40","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood.V91.2.725","volume":"91","author":"S Kurosawa","year":"1998","unstructured":"Kurosawa S, Stearns-Kurosawa DJ, Carson CW, et al. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998;91:725\u2013727.","journal-title":"Blood"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-2160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-005-2160-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-2160-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T23:57:52Z","timestamp":1626479872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-005-2160-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["2160"],"URL":"https:\/\/doi.org\/10.1007\/s10557-005-2160-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}